Meghdoot Pharma is proud to manufacture and supply Povitulle® (Povidone Iodine Tulle Dressing) to the UK National Health Service (NHS) through its UK distribution partner under their brand, Povitulle. This partnership reflects our commitment to delivering internationally compliant, high-quality wound care solutions that meet the stringent standards of one of the world's most respected public healthcare systems. By supporting patient care across NHS hospitals and healthcare facilities, Meghdoot Pharma continues to strengthen its global presence as a trusted manufacturing partner in advanced wound management. NHS procurement and supply operate through structured procurement and distribution frameworks to ensure consistent quality and continuity of supply.
Supporting UK healthcare markets with CE-certified wound dressings for distributors, importers, and professional healthcare suppliers.
The UK continues to be one of Europe's largest wound care markets, supported by an ageing population, increasing prevalence of diabetes, and the growing incidence of chronic wounds.
Industry estimates project the UK advanced wound care market to grow from USD 1.1 billion in 2026 to approximately USD 1.6 billion by 2036, representing a CAGR of 3.6%. Advanced wound dressings account for around 40% of the market, while chronic wound management represents the largest clinical segment.
As a wound dressing supplier, Meghdoot Pharma supports organisations seeking reliable access to CE-certified wound care products for professional healthcare applications.
$1.1B → $1.6B
by 2036
~40%
of market is advanced dressings
Demand for wound dressings in the UK continues to increase due to the growing number of patients requiring ongoing wound management.
KEY DEMAND DRIVERS INCLUDE:
These healthcare trends continue to support demand for quality wound dressing products across hospitals, community care, and healthcare distribution networks.
Povidone Iodine (PVP-I) dressings remain an established part of wound management within the UK. PVP-I impregnated dressings such as Inadine® have long been used in clinical practice for wound care, reflecting continued acceptance of this dressing category. Industry reports also identify antimicrobial dressings as an important segment within the expanding wound care market.
As a wound dressing exporter, Meghdoot Pharma manufactures CE-certified PVP-I wound dressings suitable for professional healthcare distribution.
We work with organisations across the UK healthcare supply chain, including:
Support includes product information, commercial quotations, regulatory documentation, and production planning.
HAVE QUESTIONS?
As an export manufacturer, Meghdoot Pharma supports the entire UK healthcare supply chain, including medical device distributors, pharmacy wholesalers, NHS supply partners, and hospital procurement teams. We supply high-quality, CE-certified wound care products backed by complete technical documentation, commercial quotations, and robust production planning to ensure consistent supply security for UK distributors.
We specialize in manufacturing CE-certified Povidone-Iodine (PVP-I) non-adherent wound dressings, an established therapeutic category widely accepted in UK clinical practice. These dressings function similarly to familiar market benchmarks like Inadine®, offering sustained broad-spectrum antimicrobial activity to manage infection risks in both acute and chronic wounds.
The UK advanced wound care market is experiencing steady expansion, valued at USD 1.1 billion in 2026 and projected to reach approximately USD 1.6 billion by 2036 at a 3.6% CAGR. Advanced dressings represent a dominant vertical within this space, accounting for roughly 40% of the entire market share, driven heavily by structured care protocols across hospitals and community networks.
The volume of dressing imports is accelerating due to a rising demographic shift, particularly an aging population that requires long-term chronic wound management. Furthermore, a high prevalence of diabetes has expanded the number of patients requiring targeted treatment for diabetic foot ulcers, pressure ulcers, venous leg ulcers, and intensive post-operative care.
Yes. Because our entire sterile wound care portfolio is CE-certified and aligned with professional healthcare standards, our products provide an ideal choice for regional healthcare distributors and institutional purchasers seeking regulatory compliance, transparent batch documentation, and competitive pricing for tender submissions.
For product information, quotations, or documentation requirements for the UK market, contact our export team.
